Thymagen
A synthetic dipeptide (Glu-Trp) from the Khavinson bioregulator family, studied for thymic bioregulation and immune system support in aging.
Also referenced as: EW, Glu-Trp, Thymogen
Also appears in: Longevity
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Thymagen crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Immune. Also surfaces under Longevity for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
EW, Glu-Trp, Thymogen
No FDA label signal · 210 trials · 3214 PubMed results
Current evidence for Thymagen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Thymagen has no clinical trials that name it and 3214 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Thymagen?
Thymagen (also marketed as Thymogen) is a synthetic dipeptide with the sequence Glu-Trp (EW), classified as a thymic bioregulator within the Khavinson peptide framework. It is related to Thymalin (the full thymic extract) and Vilon (KE dipeptide) but uses a different amino acid pair proposed to have overlapping thymic effects.
How it works
- Thymic support — proposed to modulate gene expression in thymic epithelial cells, supporting T-lymphocyte maturation and thymic function during aging (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Immune reconstitution — Thymogen has been studied in the context of immunodeficiency states and post-radiation immune recovery in Russian clinical literature
Research status
- Thymogen (the EW dipeptide) has Russian regulatory approval as an immunomodulator (nasal spray formulation)
- Morozov & Khavinson (1997) reviewed the immunomodulatory effects of thymic peptide preparations (Immunology Letters, 55(1):1–4)
- Khavinson (2005) included Thymagen in the broader bioregulator review (Gerontology, 51(2):70–75)
- Clinical data exists primarily in Russian-language literature
Key considerations
- One of the few Khavinson bioregulators with any form of regulatory approval (Russian market)
- Overlaps functionally with Vilon (KE) and Thymalin — all three target thymic/immune function
- Available from research vendors as lyophilized powder, capsules, or nasal spray
- The EW dipeptide has slightly more published clinical data than most other Khavinson short peptides